Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 59

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 59
---
 provide value to participants if the Company’s stock price appreciates. The Compensation Committee further believes these awards enable us to attract and retain key talent in our industry and aligns our executive officers’ interests with the long-term interests of our stockholders.

Generally, in determining the size of the equity awards granted to our executive officers the Compensation Committee takes into consideration the recommendations of our CEO (except with respect to his own equity award), as well as the factors described above. The Compensation Committee also considers the dilutive effect of our long-term incentive compensation practices, and the overall impact that these equity awards, as well as awards to other employees, will have on stockholder value.

In December 2023, the Compensation Committee approved equity awards for our executive officers, including our Named Executive Officers, in recognition of our financial and operational results and each executive officer’s individual performance for 2023, as well as for retentive purposes. In determining the amount of each executive officer’s equity award, the Compensation Committee took into consideration the recommendations of our CEO (except with respect to his own equity award), as well as the factors described above. The Compensation Committee also considered the existing equity holdings of each executive officer, including the current economic value of their unvested equity awards and the ability of these unvested holdings to satisfy our retention objectives.

These equity awards consisted of both options to purchase shares of our Common Stock and RSU awards that may be settled for shares of our Common Stock. The equity awards approved in December 2023 and granted to our Named Executive Officers in January 2024 were as follows:

| Named Executive Officer        |     |      Stock Options 
 (Number of Shares) |     |         RSU Awards 
 (Number of Shares) |
| Carsten Brunn, Ph.D.           |     |            199,033 |     |            155,136 |
| Blaine Davis                   |     |            103,666 |     |             80,800 |
| Metin Kurtoglu, M.D., Ph.D.(1) |     |             65,499 |     |             51,033 |
| Christopher Jewell, Ph.D.(2)   |     |             33,265 |     |             25,940 |

(1) Dr. Kurtoglu was appointed to serve as the Company’s Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer